These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22229414)

  • 1. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
    Nahta R
    Curr Med Chem; 2012; 19(7):1065-75. PubMed ID: 22229414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her2 cross talk and therapeutic resistance in breast cancer.
    Bender LM; Nahta R
    Front Biosci; 2008 May; 13():3906-12. PubMed ID: 18508484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
    Chung A; Cui X; Audeh W; Giuliano A
    Clin Breast Cancer; 2013 Aug; 13(4):223-32. PubMed ID: 23829888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
    Gajria D; Chandarlapaty S
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.
    Lavaud P; Andre F
    BMC Med; 2014 Aug; 12():132. PubMed ID: 25285786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
    Joshi JP; Brown NE; Griner SE; Nahta R
    Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
    Wang SE; Xiang B; Zent R; Quaranta V; Pozzi A; Arteaga CL
    Cancer Res; 2009 Jan; 69(2):475-82. PubMed ID: 19147560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
    Puglisi F; Minisini AM; De Angelis C; Arpino G
    Drugs; 2012 Jun; 72(9):1175-93. PubMed ID: 22686613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
    Lazaro G; Smith C; Goddard L; Jordan N; McClelland R; Barrett-Lee P; Nicholson RI; Hiscox S
    Endocr Relat Cancer; 2013 Oct; 20(5):691-704. PubMed ID: 23900794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
    Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
    Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.
    Collins DC; Cocchiglia S; Tibbitts P; Solon G; Bane FT; McBryan J; Treumann A; Eustace A; Hennessy B; Hill AD; Young LS
    Oncogene; 2015 Jan; 34(4):525-30. PubMed ID: 24469058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
    Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
    Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
    Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
    PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.